Mooss A N, Hilleman D E, Rysavy J, Sketch M H
Division of Cardiology, Creighton University School of Medicine, Omaha.
Chest. 1992 May;101(5):1438-41. doi: 10.1378/chest.101.5.1438.
To assess the effects of verapamil on postextrasystolic potentiation (PESP), contrast left ventriculography was performed in ten healthy anesthetized dogs before and after the intravenous administration of verapamil, 0.1 mg/kg. During the contrast ventriculography, a single atrial premature stimulus was introduced. Ejection fractions of a control beat and postpremature beat were measured before and after verapamil. Before verapamil, the mean ejection fractions of the control beat and the postpremature beat were 60 +/- 10 percent and 67 +/- 10 percent, respectively (p less than 0.05). Following the administration of verapamil, the mean ejection fraction of the control beat decreased from 60 +/- 10 percent to 55 +/- 11 percent (p less than 0.05). However, the mean ejection fraction of the postpremature beats increased when compared with the control beats following intravenous verapamil (65 +/- 8 percent and 55 +/- 11 percent, respectively; p less than 0.05). These results suggest that PESP is not inhibited by the administration of intravenous verapamil.
为评估维拉帕米对早搏后增强作用(PESP)的影响,对10只健康麻醉犬在静脉注射0.1mg/kg维拉帕米前后进行了对比左心室造影。在对比心室造影期间,引入单个房性早搏刺激。在维拉帕米给药前后测量对照搏动和早搏后搏动的射血分数。在维拉帕米给药前,对照搏动和早搏后搏动的平均射血分数分别为60±10%和67±10%(p<0.05)。给予维拉帕米后,对照搏动的平均射血分数从60±10%降至55±11%(p<0.05)。然而,与静脉注射维拉帕米后的对照搏动相比,早搏后搏动的平均射血分数增加(分别为65±8%和55±11%;p<0.05)。这些结果表明,静脉注射维拉帕米不会抑制PESP。